To examine the role of gut microbiome dysbiosis in the pathogenesis of Polycystic Ovary Syndrome (PCOS) and explore potential microbiome-based treatments.
Key Findings:
Gut dysbiosis and intestinal barrier dysfunction are pivotal in the onset and progression of PCOS.
Distinct gut microbial signatures in PCOS patients correlate with hyperandrogenism and insulin resistance.
Fecal microbiota transplantation studies indicate a causal role of gut microbiota in PCOS pathogenesis.
Interpretation:
The gut microbiome is not merely a bystander in PCOS but may actively contribute to the endocrine-metabolic disturbances associated with the syndrome.
Limitations:
Uncertainty remains whether microbial dysbiosis is a primary driver or a secondary amplifier in PCOS development.
Current therapeutic strategies may yield suboptimal outcomes for some patients.
Conclusion:
Microbiome-targeted therapies present a novel avenue for PCOS treatment, potentially improving outcomes by addressing underlying metabolic and endocrine dysfunctions.
